Over the last two decades, fluorine substitution has become one of the essential structural
traits in modern pharmaceuticals. Thus, about half of the most successful drugs (blockbuster …

Experimenta naturae, like the glucose-6-phosphate dehydrogenase deficiency, indicate that
malaria parasites are highly susceptible to alterations in the redox equilibrium. This offers a …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Present elimination strategies are based on recommendations derived during the Global
Malaria Eradication Program of the 1960s. However, many countries considering elimination …

That primaquine and other drugs can trigger acute haemolytic anaemia in subjects who
have an inherited mutation of the glucose 6‐phosphate dehydrogenase (G6 PD) gene has …

Approximately 40% of the world population live in areas with the risk of malaria. Each year,
300–500 million people suffer from acute malaria, and 0.5–2.5 million die from the disease …

Primaquine was firstly synthesized in 1946 in the USA, and is the most representative
member of the anti-malarial 8-aminoquinolines. Six decades have passed and primaquine …

Abstract Glucose-6-phosphate dehydrogenase (G6PD) is a potentially pathogenic inherited
enzyme abnormality and, similar to other human red blood cell polymorphisms, is …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …